Biospecifics Technologies (BSTC)
Biospecifics Technologies Profit Margin: 28.70%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BSTC Profit Margin Rankings
| Overall | 94th percentile | 231 of 4391 |
| Sector | 95th percentile | 21 of 469 in Healthcare |
| Industry | 90th percentile | 12 of 132 in Biotechnology |
BSTC Profit Margin Range, Past 5 Years
| Minimum | -539.4% | Dec 2007 |
| Maximum | 72.28% | Dec 2008 |
| Average | -84.97% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these BSTC related companies
BSTC News
BioSpecifics Technologies Corp. Reports First Quarter 2012 Financial Results
May 10, 4:00PM PR Newswire
May 10, 4:00PM PR Newswire
BioSpecifics Technologies Corp Announces Initiation of Phase II Trial for Canine Lipomas
May 07, 7:33AM Benzinga
May 07, 7:33AM Benzinga
BioSpecifics Technologies Corp. Announces Initiation of Phase II Trial for Canine Lipomas
May 07, 7:30AM PR Newswire
May 07, 7:30AM PR Newswire
$BSTC filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aVw
about 28 days ago by MarketBrief
about 28 days ago by MarketBrief
MKM Starts BioSpecifics Technologies (BSTC) at Buy, Sets $26.50 Target
Apr 05, 12:26PM Street Insider
Apr 05, 12:26PM Street Insider
UPDATE: Stifel Nicolaus Initiates Buy, $29 Target on BioSpecifics Technologies
Mar 15, 12:03PM Benzinga
Mar 15, 12:03PM Benzinga
Listen to $BSTC Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2kxD
about 80 days ago by earningscast
about 80 days ago by earningscast
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 09, 7:30AM PR Newswire
Mar 09, 7:30AM PR Newswire
BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
Dec 09, 8:00AM PR Newswire
Dec 09, 8:00AM PR Newswire
BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 09, 8:00AM PR Newswire
Nov 09, 8:00AM PR Newswire
BioSpecifics Technologies Corp. Reports Third Quarter 2011 Financial Results
Nov 08, 7:30AM PR Newswire
Nov 08, 7:30AM PR Newswire
$BSTC $23.79 Geller Matthew director S 12,300 @ $24.01 amnt $295,325 proc'd $2,755 5/23/2011
about 370 days ago by canarionyc
about 370 days ago by canarionyc
RT @HCPG http://nyti.ms/cJKu4Q &lt;--Um, did you just put $AUXL & $BSTC on your watch list like I did?
about 804 days ago by RAEckart
about 804 days ago by RAEckart
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BSTC | 16.39 | -0.01 | -0.06% | 103.91M |
| BSRR | 9.01 | +0.06 | +0.67% | 127.04M |
| BSQR | 2.65 | -0.02 | -0.75% | 28.86M |
| BSP | 8.43 | +0.00 | +0.00% | |
| BSI | 2.555 | +0.01 | +0.59% | 168.60M |
| CB | 71.75 | -0.35 | -0.49% | 19.40B |
| CAW | 4.06 | +0.06 | +1.50% | 28.62M |
| CAVM | 23.77 | -0.09 | -0.38% | 1.174B |
| CATY | 16.68 | -0.18 | -1.07% | 1.312B |
| CATO | 29.33 | +0.53 | +1.84% | 804.23M |
